Abstract
Immunoconjugates are essential tools in diagnostics for the detection and quantification of proteins and in cell biology for the characterization of different cell populations as well as for tracking intracellular pathways. In recent years, antibody–drug conjugates (ADCs) have emerged as promising therapeutics to treat cancer and have moved into the focus of interest of the pharmaceutical industry. Here we describe a conjugation method for the generation of antibody conjugates that relies on the formation of a spontaneous isopeptide bond between two peptide tags referred to as SpyTag and KTag. This reaction is catalyzed by SpyLigase, an engineered cell surface protein obtained from Streptococcus pyogenes. We describe the preparation of SpyLigase by expression from E. coli cells, chemical solid-phase synthesis of the KTag peptide and its coupling to reporter molecules and cytotoxins as well as the transient expression from mammalian cells to produce Spy-tagged antibodies. Furthermore, we describe the purification and analytics of the formed conjugates.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Lambert JM, Berkenblit A (2018) Antibody–drug conjugates for cancer treatment. Annu Rev Med 69:191–207
Ducry L (2012) Challenges in the development and manufacturing of antibody-drug conjugates. Methods Mol Biol 899:489–497
Wagh A, Song H, Zeng M et al (2018) Challenges and new frontiers in analytical characterization of antibody-drug conjugates. MAbs 10:222–243
Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063–7070
Sun X, Ponte JF, Yoder NC et al (2017) Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates. Bioconjug Chem 28:1371–1381
Schumacher D, Hackenberger CPR, Leonhardt H et al (2016) Current status: site-specific antibody drug conjugates. J Clin Immunol 36:100–107
Junutula JRJR, Raab H, Clark S et al (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925–932
Badescu G, Bryant P, Bird M et al (2014) Bridging disulfides for stable and defined antibody drug conjugates. Bioconjug Chem 25:1124–1136
Jones MW, Strickland RA, Schumacher FF et al (2012) Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. J Am Chem Soc 134:1847–1852
Maruani A, Smith MEB, Miranda E et al (2015) A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. Nat Commun 6:6645
Beerli RR, Hell T, Merkel AS et al (2015) Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency. PLoS One 10:e0131177
Dennler P, Chiotellis A, Fischer E et al (2014) Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody–drug conjugates. Bioconjug Chem 25:569–578
Strop P, Liu SH, Dorywalska M et al (2013) Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20:161–167
Lhospice F, Brégeon D, Belmant C et al (2015) Site-specific conjugation of monomethyl auristatin e to anti-CD30 antibodies improves their pharmacokinetics and therapeutic index in rodent models. Mol Pharm 12:1863–1871
Siegmund V, Piater B, Zakeri B et al (2016) Spontaneous isopeptide bond formation as a powerful tool for engineering site-specific antibody-drug conjugates. Sci Rep 6:39291
Kang HJ, Coulibaly F, Clow F et al (2007) Stabilizing isopeptide bonds revealed in gram-positive bacterial pilus structure. Science 318:1625–1628
Zakeri B, Fierer JO, Celik E et al (2012) Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A 109:E690–E697
Zakeri B, Howarth M (2010) Spontaneous intermolecular amide bond formation between side chains for irreversible peptide targeting. J Am Chem Soc 132:4526–4527
Fierer JO, Veggiani G, Howarth M (2014) SpyLigase peptide-peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture. Proc Natl Acad Sci U S A 111:E1176–E1181
Buldun CM, Jean JX, Bedford MR et al (2018) SnoopLigase catalyzes peptide-peptide locking and enables solid-phase conjugate isolation. J Am Chem Soc 140:3008–3018
Lefranc MP (2003) IMGT, the international ImMunoGeneTics database®. Nucleic Acids Res 31(1):307
Acknowledgments
This protocol has been developed within a project that has been funded by Merck KGaA Darmstadt in the context of the Merck Biopharma Innovation Cup. The authors thank Ulrich A. K. Betz and the members of the team Chemo- and Bioengineering namely Bijan Zakeri, Pedro Matos, Sara Cleto, Darryl Gibbings-Isaac, and Reswita Dery G from the Innovation Cup 2013 and Siegfried Neumann for giving inspiration for this project.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Siegmund, V., Piater, B., Fischer, F., Kolmar, H. (2019). SpyLigase-Catalyzed Modification of Antibodies. In: Nuijens, T., Schmidt, M. (eds) Enzyme-Mediated Ligation Methods. Methods in Molecular Biology, vol 2012. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9546-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9546-2_10
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9545-5
Online ISBN: 978-1-4939-9546-2
eBook Packages: Springer Protocols